Plain-English translation of NCT07100405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is observing how people with advanced liver cancer respond to a combination treatment approach: a procedure called TACE (which delivers chemotherapy directly into liver tumors) plus a (an immunotherapy medication that helps your immune system fight cancer). Researchers will track how well this combination works and study how the treatment changes your immune system's response to the cancer.
Advanced liver cancer is difficult to treat, and doctors are exploring whether combining a targeted tumor procedure with immunotherapy might help patients live longer and have better outcomes than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive TACE (a procedure performed by your doctor to deliver medicine directly into liver tumors) combined with a medication as your first-line cancer treatment. Throughout the study, you would have regular clinic visits for imaging scans, blood tests, and lab work to monitor how you're responding. You would also be asked to provide blood samples and allow researchers to study tissue from your tumor before treatment begins and at certain times afterward to understand how the treatment affects your immune system.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Sponsor
Fudan University
Enrollment target
~50 participants
Started
August 2025
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peng Wang, MD
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.